Archive

Neovasc Announces Receipt of German NUB Status 1 Designation for Neovasc Reducer™ Procedure for Treatment of Refractory Angina

Posted on February 1, 2018
in
by

Participating Hospitals in Germany Now Eligible to Negotiate Reimbursement for Reducer Procedure NASDAQ, TSX: NVCN VANCOUVER, Feb. 1, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies, today announced that the "Institut...

Read More

Fred Colen Appointed Chief Executive Officer of Neovasc Inc.

Posted on January 22, 2018
in
by

Recognized Multinational Senior Executive Poised to Drive Commercialization and Clinical Advances NASDAQ, TSX: NVCN VANCOUVER, Jan. 22, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq, TSX: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has...

Read More

Neovasc Reducer Featured in Live Case at Berlin Symposium

Posted on January 18, 2018
in
by

NASDAQ, TSX: NVCN VANCOUVER, Jan. 18, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq, TSX: NVCN) today reported its Neovasc Reducer™ ("Reducer") was featured in a "live case" broadcast to more than 800 participants at the Kardiologie Symposium 2018 held in Berlin, Germany.  The successful live case was...

Read More

Neovasc Reports Tiara’s Clinical Case Load Accelerating

Posted on January 8, 2018
in
by

- 10 new implants performed in the past 60 days -  NASDAQ, TSX: NVCN VANCOUVER, Jan. 8, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today provided an update on its clinical program for the Tiara™ ("Tiara") valve, a self-expanding mitral bioprosthesis for...

Read More

Neovasc Receives NASDAQ Notification Regarding Minimum Bid Requirements

Posted on January 2, 2018
in
by

VANCOUVER, Jan. 2, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX:NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid...

Read More

Neovasc Reducer Featured in Live Case at ICI 2017

Posted on December 6, 2017
in
by

- Clinical updates for both Reducer™ and Tiara™ also presented at premier event - NASDAQ, TSX: NVCN VANCOUVER, Dec. 6, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported its Neovasc Reducer™ ("Reducer") medical device was featured in a "live case"...

Read More

Neovasc to Present at the Piper Jaffray 29th Annual Healthcare Conference

Posted on November 27, 2017
in
by

NASDAQ, TSX: NVCN VANCOUVER, Nov. 27, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that Chris Clark, chief financial officer, is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29th at 7:50 am...

Read More